Biogen Idec Is Evaluating Strategic Options For Zevalin

The biotech is considering divesting or partnering the non-Hodgkin’s B-cell lymphoma treatment.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet